{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:28:48Z","timestamp":1792024128149,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.expneurol.2008.06.004","type":"journal-article","created":{"date-parts":[[2008,6,15]],"date-time":"2008-06-15T15:08:23Z","timestamp":1213542503000},"page":"315-325","source":"Crossref","is-referenced-by-count":344,"title":["Direct quantification of CSF \u03b1-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration"],"prefix":"10.1016","volume":"213","author":[{"given":"Brit","family":"Mollenhauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Cullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Krastins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago F.","family":"Outeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imelda","family":"Pepivani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Schulz-Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans A.","family":"Kretzschmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Trenkwalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Sarracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"VonSattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Locascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar M.A.","family":"El-Agnaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Schlossmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2008.06.004_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","article-title":"Mice lacking [alpha]-synuclein display functional deficits in the nigrostriatal dopamine system","volume":"25","author":"Abeliovich","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.expneurol.2008.06.004_bib2","doi-asserted-by":"crossref","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser 129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease","volume":"281","author":"Anderson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2008.06.004_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archneur.56.6.673","article-title":"Cerebrospinal fluid beta-amyloid(1\u201342) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease","volume":"56","author":"Andreasen","year":"1999","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener Dis."},{"key":"10.1016\/j.expneurol.2008.06.004_bib5","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/nm1438","article-title":"Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo","volume":"12","author":"Bateman","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.expneurol.2008.06.004_bib6","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1093\/brain\/awl063","article-title":"CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia","volume":"129","author":"Bibl","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2008.06.004_bib7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(03)00530-1","article-title":"CSF markers for incipient Alzheimer's disease","volume":"2","author":"Blennow","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.expneurol.2007.08.006","article-title":"In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?","volume":"209","author":"Chesselet","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/1097-0029(20010101)52:1<65::AID-JEMT9>3.0.CO;2-4","article-title":"Choroid plexus: target for polypeptides and site of their synthesis","volume":"52","author":"Chodobski","year":"2001","journal-title":"Microsc. Res. Tech."},{"key":"10.1016\/j.expneurol.2008.06.004_bib10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1073\/pnas.97.2.571","article-title":"Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy","volume":"97","author":"Conway","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2008.06.004_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.biochem.74.082803.133400","article-title":"The biochemistry of Parkinson's disease","volume":"74","author":"Cookson","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.expneurol.2008.06.004_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.expneurol.2007.05.022","article-title":"Cell systems and the toxic mechanism(s) of alpha-synuclein","volume":"209","author":"Cookson","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib13","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1126\/science.1101738","article-title":"Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy","volume":"305","author":"Cuervo","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2008.06.004_bib14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.bjp.0707441","article-title":"Biomarker method validation in anticancer drug development","volume":"153","author":"Cummings","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1586\/14737175.6.6.823","article-title":"Biomarkers in Parkinson's disease","volume":"6","author":"Dorsey","year":"2006","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.expneurol.2008.06.004_bib16","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","article-title":"Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria","volume":"6","author":"Dubois","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-5793(98)01418-5","article-title":"Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments","volume":"440","author":"El-Agnaf","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1016\/j.expneurol.2008.06.004_bib18","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1096\/fj.03-0098fje","article-title":"Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma","volume":"17","author":"El-Agnaf","year":"2003","journal-title":"Faseb J."},{"key":"10.1016\/j.expneurol.2008.06.004_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1096\/fj.03-1449com","article-title":"Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease","volume":"20","author":"El-Agnaf","year":"2006","journal-title":"Faseb J."},{"key":"10.1016\/j.expneurol.2008.06.004_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","article-title":"Cerebrospinal fluid tau\/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults","volume":"64","author":"Fagan","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib21","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2008.06.004_bib22","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nrg1831","article-title":"Genetics of Parkinson disease: paradigm shifts and future prospects","volume":"7","author":"Farrer","year":"2006","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.expneurol.2008.06.004_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00365510601161497","article-title":"Determination of alpha-synuclein concentration in human plasma using ELISA","volume":"67","author":"Fjorback","year":"2007","journal-title":"Scand J. Clin. Lab. Invest."},{"key":"10.1016\/j.expneurol.2008.06.004_bib24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1212\/01.wnl.0000254458.17630.c5","article-title":"Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication","volume":"68","author":"Fuchs","year":"2007","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.expneurol.2008.06.004_bib25","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1096\/fj.07-9348com","article-title":"Genetic variability in the SNCA gene influences {alpha}-synuclein levels in the blood and brain","volume":"22","author":"Fuchs","year":"2008","journal-title":"Faseb J"},{"key":"10.1016\/j.expneurol.2008.06.004_bib26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(05)79256-4","article-title":"Multiple-system atrophy: a new alpha-synuclein disease?","volume":"352","author":"Gai","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2008.06.004_bib27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1136\/pgmj.64.751.345","article-title":"Accuracy in the clinical diagnosis of parkinsonian syndromes","volume":"64","author":"Gibb","year":"1988","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.expneurol.2008.06.004_bib28","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/ana.20477","article-title":"Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease","volume":"57","author":"Grossman","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.expneurol.2007.07.006","article-title":"Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms","volume":"209","author":"Halliday","year":"2008","journal-title":"Exp. Neurol."},{"issue":"Suppl 6","key":"10.1016\/j.expneurol.2008.06.004_bib31","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/mds.10557","article-title":"Neuropathological spectrum of synucleinopathies","volume":"18","author":"Jellinger","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2008.06.004_bib32","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2007.12.040","article-title":"Active caspase-1 is a regulator of unconventional protein secretion","volume":"132","author":"Keller","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.expneurol.2008.06.004_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncpneuro0126","article-title":"The genetics of Parkinson disease: implications for neurological care","volume":"2","author":"Klein","year":"2006","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib34","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1523\/JNEUROSCI.4564-06.2007","article-title":"Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies","volume":"27","author":"Kramer","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2008.06.004_bib36","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1523\/JNEUROSCI.0692-05.2005","article-title":"Intravesicular localization and exocytosis of alpha-synuclein and its aggregates","volume":"25","author":"Lee","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2008.06.004_bib37","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1373\/clinchem.2005.058776","article-title":"Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides","volume":"52","author":"Lewczuk","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/j.expneurol.2008.06.004_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3233\/JAD-2002-4406","article-title":"Platelet alpha- and gamma-synucleins in Parkinson's disease and normal control subjects","volume":"4","author":"Li","year":"2002","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.expneurol.2008.06.004_bib39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.expneurol.2006.12.006","article-title":"Plasma alpha-synuclein is decreased in subjects with Parkinson's disease","volume":"204","author":"Li","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib40","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/WNL.47.5.1113","article-title":"Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop","volume":"47","author":"McKeith","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2008.06.004_bib41","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2008.06.004_bib42","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2008.06.004_bib43","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/brain\/awh198","article-title":"Biomarkers and Parkinson's disease","volume":"127","author":"Michell","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2008.06.004_bib44","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1365-2680.2000.00198.x","article-title":"Dopamine receptor immunohistochemistry in the rat choroid plexus","volume":"20","author":"Mignini","year":"2000","journal-title":"J. Auton Pharmacol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib45","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1212\/01.WNL.0000127517.33208.F4","article-title":"Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication","volume":"62","author":"Miller","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2008.06.004_bib47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00415-003-1059-3","article-title":"Diagnostic problems during late course in Creutzfeldt\u2013Jakob disease","volume":"250","author":"Mollenhauer","year":"2003","journal-title":"J. Neurol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib48","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00702-004-0235-7","article-title":"Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease","volume":"112","author":"Mollenhauer","year":"2005","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.expneurol.2008.06.004_bib49","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000083178","article-title":"Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies","volume":"19","author":"Mollenhauer","year":"2005","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.expneurol.2008.06.004_bib50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1515\/CCLM.2006.035","article-title":"Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1\u201342), and beta-amyloid(1\u201340) in cerebrospinal fluid of patients with dementia with Lewy bodies","volume":"44","author":"Mollenhauer","year":"2006","journal-title":"Clin. Chem. Lab. Med."},{"issue":"Suppl 15","key":"10.1016\/j.expneurol.2008.06.004_bib51","article-title":"Proteome analysis of cerebrospinal fluid by mass spectrometry: a platform for marker development in synucleinopathies","volume":"21","author":"Mollenhauer","year":"2006","journal-title":"Movement Disorders"},{"key":"10.1016\/j.expneurol.2008.06.004_bib52","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1159\/000094871","article-title":"Beta-amyloid 1\u201342 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia","volume":"22","author":"Mollenhauer","year":"2006","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.expneurol.2008.06.004_bib53","series-title":"Parkinson's Disease: Pathogenic and Therapeutic Insights, vol. 41","first-page":"559","article-title":"Purification and quantification of neural alpha-synuclein: Relevance for pathogenesis and biomarker development","author":"Mollenhauer","year":"2008"},{"key":"10.1016\/j.expneurol.2008.06.004_bib54","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ana.410380413","article-title":"Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease","volume":"38","author":"Motter","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib55","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.20753","article-title":"Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease","volume":"59","author":"Nishioka","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib56","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1212\/WNL.58.2.192","article-title":"Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt\u2013Jakob disease","volume":"58","author":"Otto","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2008.06.004_bib57","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1126\/science.1090439","article-title":"Yeast cells provide insight into alpha-synuclein biology and pathobiology","volume":"302","author":"Outeiro","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2008.06.004_bib58","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1523\/JNEUROSCI.0285-07.2007","article-title":"Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo","volume":"27","author":"Periquet","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.expneurol.2008.06.004_bib59","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2008.06.004_bib60","first-page":"79","article-title":"Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics","volume":"21","author":"Reiber","year":"2003","journal-title":"Restor Neurol. Neurosci."},{"key":"10.1016\/j.expneurol.2008.06.004_bib61","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nbt0806-914","article-title":"What brown cannot do for you","volume":"24","author":"Rimm","year":"2006","journal-title":"Nat. Biotechnol."},{"issue":"3","key":"10.1016\/j.expneurol.2008.06.004_bib62","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1073\/pnas.0610204104","article-title":"Molecular markers of early Parkinson's disease based on gene expression in blood","volume":"104","author":"Scherzer","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2008.06.004_bib63","series-title":"The Dementias 2","first-page":"184","article-title":"Alpha-synuclein and synucleinopathies","author":"Schlossmacher","year":"2007"},{"issue":"026","key":"10.1016\/j.expneurol.2008.06.004_bib64","article-title":"Monitoring of alpha-synuclein steady-state levels in vivo by ELISA","volume":"21","author":"Schlossmacher","year":"2006","journal-title":"Movement disorders"},{"key":"10.1016\/j.expneurol.2008.06.004_bib65","first-page":"351","article-title":"Parkinson's disease: assays for the ubiquitin ligase activity of neural Parkin","volume":"301","author":"Schlossmacher","year":"2005","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.expneurol.2008.06.004_bib66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/359325a0","article-title":"Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids","volume":"359","author":"Seubert","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2008.06.004_bib68","doi-asserted-by":"crossref","first-page":"23727","DOI":"10.1074\/jbc.M503326200","article-title":"The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates {alpha}-synuclein degradation decisions between proteasomal and lysosomal pathways","volume":"280","author":"Shin","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2008.06.004_bib69","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1021\/bi0120906","article-title":"Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease?","volume":"41","author":"Shtilerman","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.expneurol.2008.06.004_bib70","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1090278","article-title":"Alpha-synuclein locus triplication causes Parkinson's disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2008.06.004_bib71","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.expneurol.2008.06.004_bib72","doi-asserted-by":"crossref","first-page":"9549","DOI":"10.1523\/JNEUROSCI.21-24-09549.2001","article-title":"Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death","volume":"21","author":"Stefanis","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2008.06.004_bib73","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbrc.2006.08.024","article-title":"Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease","volume":"349","author":"Tokuda","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.expneurol.2008.06.004_bib74","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jneumeth.2007.09.021","article-title":"A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid","volume":"168","author":"van Geel","year":"2008","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.expneurol.2008.06.004_bib75","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/brain\/awl076","article-title":"Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein","volume":"129","author":"Wadsworth","year":"2006","journal-title":"Brain"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488608002562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488608002562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T23:53:00Z","timestamp":1557618780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488608002562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S0014488608002562"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2008.06.004","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}